In that same line of thought I have written an email to

New Post Public Reply Private Reply Replies (3) Message Board
Zolis_onkel Beasley #30644
485
In that same line of thought I have written an email to Todd yesterday, and since he is usually quite quick in responding and has not so far, I just share at least my message to him with y'all!
(Remark: Y'all is one of the those things that I still remember from my time in Houston, TX. Howdy, y'all! LOL )!

So here is the original email text I sent to Todd yesterday, with again no reply so far. Should he respond, and in case I receive his permission, I will share his response with you, but after almost 24h after I had sent it, I do not count on any answer anymore.

%%%%% Original Email Text %%%%%%

Subject: When are you going to break the silence?

Hey Todd,

it again has been a while, but the silence we, GNBT's loyal shareholders, receive for more than two months now, ie. after the CC that had us all pretty excited, is deafening. Which is why I am now breaking my silence towards you, and want to let you in on some of the most pressing questions a lot of GNBT shareholders have, as I know from my regular participation in several GNBT/NGIO related message boards in the US and here in Germany.

What happened to all the prospects mentioned during that last CC?
Olaregen was supposed to receive non-dilutive funds to market-launch Excellegen! Has that happened as predicted during the CC? If yes, why haven't we publicly heard anything about that yet? I suppose an official PR announcement of potential profits regularly pouring into the company soon, could have the potential to stop the constant downturn of the share price. If no, what happened with that, and why haven't we heard about that, and what is Olaregen going to do about it? Is there a plan B?

In regards to the vaccine development, there was a timeline mentioned during the CC. Are you still on track of that? What are the next steps? When can we count on the filing of the IND package to the FDA? How long do you expect the approval to take? Is this going to be short, because of the Pre-IND application that you have been closely working with the FDA on? Are we talking days, weeks or months? When do you estimate that the Phase I clinical trials might start? And based on the company's best estimates, when could a final FDA approval happen earliest?

In regards to the NGIO IPO, can we get any update as to when this might happen? In January Joe publicly said in an interview that he estimates to have NGIO trading on Nasdaq within 30 to 60 days, now even the 60 day deadline lies almost 4 months in the past, and neither is NGIO listed on Nasdaq, nor do we know if it ever will, and if yes, when that is going to happen. Are you currently purposefully postponing this IPO until the FDA submission/approval of the IND package has happened? If yes, why exactly is that? If not, what else is holding it back/keeps it from happening?

In order for this email not to get even longer, I guess you get it, that there are a hell of a lot of questions that I, as a long term shareholder of GNBT, am currently asking myself, and I think all GNBT shareholders deserve answers to. Please stop keeping us in the dark, and publish a general update on all of the "stuff" that was discussed during the last CC, and is currently going on within the company and its subs, including next milestones and reliable timelines. It would be most appreciated if you can then find a format (e.g. a company Twitter account, or your homepage, or alike), where you can easily and at little to no cost provide regular updates on all of your initiatives, to your shareholders.

Thanks in advance. Your answer, be it personally to this email, or publicly via PR or other announcement, would be highly appreciated.

Best regards from Germany
xxx

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 594

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 157

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 547

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 308

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 505

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 421

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 453

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 281

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 499

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antengene's XPOVIO® Gains Approval in Thailand for Cancer Treatment

Updated Category News Views 114

Antengene's Recent Approval of XPOVIO® in Thailand Antengene Corporation Limited, a distinguished global biopharmaceutical company, has reached a notable achievement with the approval of XPOVIO® (selinexor) by the Thailand Food and Drug Administration. This approval marks XPOVIO® as the first and only XPO1 inhibitor authorized for sale in the Thai market. The drug,...

Continue Reading
Monumental Pediatric Surgery Advances at Nicklaus Children

Updated Category News Views 23

Redefining Pediatric Surgery with Mixed Reality Cue the drumroll, because Nicklaus Children's Hospital in Miami just pulled off a doozy in the medical field. The region's first pediatric total hip replacement using mixed reality-assisted guidance has taken place, and the ripples from this bad boy could be significant. The Hero of the Hour: Dr. Thomas J. Utset-Ward Dr....

Continue Reading
Contrasting Luxury Real Estate Trends in the U.S. Market

Updated Category News Views 151

The Evolving Landscape of U.S. Luxury Real Estate In the world of luxury real estate, change is the only constant. A recent report sheds light on how the U.S. luxury housing market is adapting to buyer preferences, with 2026 marking an interesting phase in pricing stabilization. Nationally, entry-level luxury prices stand steady at $1.19 million, but the interpretation of...

Continue Reading
Bureau Veritas Explores Potential Merger with SGS

Updated Category News Views 325

Exploring Business Synergies: Bureau Veritas and SGS Recent media discussions have shed light on the evolving landscape of Bureau Veritas as it engages in talks with SGS about the possibility of a business merger. This potential union reflects the growing trend within industries to enhance competencies and create greater value through collaboration. Bureau Veritas, a...

Continue Reading
Equifax Engages Investors in September Conferences Overview

Updated Category News Views 133

Equifax Invites Investors to Upcoming Conferences Equifax®, a leading data, analytics, and technology company recognized by its stock symbol EFX on the NYSE, is gearing up to engage with investors through several key conferences this September. This month presents an excellent opportunity for investors to gain insights into the company's strategy and future direction....

Continue Reading